Frequent yeast infections

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Frequent Yeast Infections: Causes, Pathogenesis, and Treatment

Immunosuppression and Opportunistic Yeast Infections

Frequent yeast infections are often linked to immunosuppression. Patients with compromised immune systems, such as those with hematological malignancies or advanced HIV, are particularly susceptible to invasive fungal infections caused by unusual yeasts. Non-albicans species of Candida, such as Candida glabrata and Candida krusei, are increasingly common and may exhibit resistance to azole antifungal therapy . Other opportunistic yeasts, including Trichosporon, Rhodotorula, and non-neoformans cryptococci, also pose significant risks to immunocompromised individuals .

Genetic Factors and Chronic Mucocutaneous Candidiasis

Chronic mucocutaneous candidiasis (CMCD) is characterized by persistent infections of the skin, nails, and mucosal surfaces. This condition is often due to genetic deficiencies in the immune response, specifically involving interleukin-17 (IL-17) pathways. Deficiencies in IL-17 receptor A (IL-17RA) and IL-17F can lead to impaired mucocutaneous immunity against Candida albicans, resulting in recurrent infections . These genetic factors highlight the importance of the host immune response in controlling yeast proliferation.

Recurrent Vulvovaginal Candidiasis (RVVC)

Recurrent vulvovaginal candidiasis (RVVC) is a common issue among women, characterized by frequent episodes of vaginal yeast infections. Unlike sporadic cases, RVVC often lacks identifiable precipitating factors. Studies indicate that non-albicans Candida species are more prevalent in RVVC cases compared to primary infections. However, resistance to azoles is not typically a causal factor in these recurrent infections . Instead, persistent yeast in the vagina, rather than frequent reinfection, is often responsible for the relapses .

Emerging Multidrug-Resistant Yeasts

Candida auris has emerged as a significant nosocomial pathogen, particularly in hospital settings. This multidrug-resistant yeast is difficult to treat and has been associated with high mortality rates in intensive care units. Candida auris exhibits resistance to fluconazole and variable susceptibility to other antifungals, making it a challenging pathogen to manage . The rapid global spread of this yeast underscores the need for vigilant infection control practices and novel therapeutic strategies.

Diagnosis and Treatment Challenges

Diagnosing yeast infections, especially those caused by uncommon species, can be challenging. Traditional culture methods remain the gold standard, but adjunctive tests like serum (1,3)-β-D-glucan can aid in diagnosis . Treatment is often complicated by antifungal resistance, particularly among non-albicans Candida species. Maintenance regimens with azoles are commonly used to control symptoms in recurrent cases, but no definitive cure exists for conditions like RVVC .

Conclusion

Frequent yeast infections are a multifaceted issue influenced by immunosuppression, genetic factors, and emerging multidrug-resistant pathogens. Effective management requires a comprehensive understanding of the underlying causes, accurate diagnosis, and tailored treatment strategies. Ongoing research and improved therapeutic options are essential to address the growing challenge of recurrent and resistant yeast infections.

Sources and full results

Most relevant research papers on this topic

Emerging opportunistic yeast infections.

Rare yeasts are emerging as opportunistic human pathogens, with diagnosis challenging and treatment suboptimal in immunosuppressed patients.

Literature ReviewRigorous Journal

2011·

787citations

·M. Miceli et al.

The Lancet. Infectious diseases·

DOI

Fifty-five-year-old man with chronic yeast infections

The differential diagnosis for recurrent yeast infections involves various immune abnormalities, including Toll-like receptor problems, atypical mycobacteria, and Candida/staphylococcal infections.

Case Report

2014·

3citations

·J. Kennedy et al.

DOI

Pathogenesis and treatment of recurrent vulvovaginal candidiasis.

Recurrent candidal vaginitis may result from an acquired Candida antigen-specific immunological deficiency, with no definitive cure but effective therapeutic maintenance regimens using azoles to control symptomatic infection.

Literature Review

1992·

262citations

·J. Sobel

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·

DOI

Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally

Candida auris, a multidrug-resistant yeast, has rapidly emerged as a global cause of hospital-acquired multidrug-resistant fungal infections, posing a significant threat to ICU patients.

2017·

658citations

·A. Chowdhary et al.

PLoS Pathogens·

DOI

Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity*

Human IL-17A and IL-17F are essential for mucocutaneous immunity against Candida albicans, but otherwise largely redundant.

2011·

1013citations

·A. Puel et al.

Science (New York, N.Y.)·

DOI

Difference Between the Profiles Presented by Yeasts that Colonize the Vaginal Mucosa or Cause Primary or Recurrent Candidiasis

Candida yeasts in vaginal secretion show a diversity of species in primary and recurrent candidiasis, with C. haemulonii being more common in symptomatic patients.

2021·

16citations

·D. Moreira et al.

Mycopathologia·

DOI

Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal

Antifungal resistance in Candida albicans bloodstream infections is influenced by factors such as biofilm formation, mutations, and host immune defenses, which can be modulated or reverted through alternative therapeutic options.

Rigorous Journal

2020·

187citations

·S. Costa-de-Oliveira et al.

Microorganisms·

DOI

Changing epidemiology of systemic fungal infections.

The epidemiology of systemic fungal infections is evolving, with emerging pathogens like Zygomycetes, Fusarium spp., and Scedosporium spp. requiring individualized antifungal treatment based on patient characteristics and pathogen susceptibility patterns.

Literature Review

2008·

525citations

·M. Richardson et al.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·

DOI

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections.

This paper provides guidelines for diagnosing and managing rare invasive yeast infections, focusing on microbiological investigation and antifungal susceptibility testing.

2014·

494citations

·M. Arendrup et al.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·

DOI

Invasive fungal infections: a review of epidemiology and management options.

Invasive fungal infections are a major pathogen in critically ill patients, with increased incidence due to the use of antineoplastic, immunosuppressive agents, broad-spectrum antibiotics, prosthetic devices, and aggressive surgery.

2006·

499citations

·D. Enoch et al.

Journal of medical microbiology·

DOI

Try another search

earth universe

science phy

molnupiravir side effects

point of no return black hole

how long does it take for ibuprofen to kick in

prescription migraine medicine